News

Sean Hanlon, CEO of CoFi, a payment software company, talks about the company's recent integration with CareCredit.

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Ula Jurkunas, MD, sat down to discuss her presentation on the management of anterior corneal disease at this year's ASCRS meeting held in Boston, Massachusetts.

Rich Small, CEO of Neurotech Pharmaceuticals, provides an update on the months ahead for NT-501 encapsulated cell therapy

Roger Kennedy, director of marketing at BioTissue sat down to discuss the new products the company will be unveiling at this year's ASCRS meeting held in Boston, Massachusetts.

Jennifer Loh, MD, sat down to discuss her presentation on major eye issues that can interfere with refractive cataract surgery, specifically dry eye disease, at this year's ASCRS meeting held in Boston, Massachusetts.

Spencer will formally receive his award during the 2024 ASCRS Annual meeting, being held April 5 to 8, as part of its 50th anniversary celebration.

Diabetic macular edema is often treated with dexamethasone intravitreal implant, and bevacizumab. While they both treat the same disease, they work in different ways.

Modern Retina’s interview with Aracelis Torres, PhD, MPH sheds light on how real-world insights empower researchers to see trends and develop new strategies, sometimes even new products, to meet the treatment needs of patients.

Zeiss has secured regulatory approvals to acquire DORC, and the companies will now shift their focus to integration implementation.

The company said the module, which includes real-world data on more than 10 million patients, will help advance research and accelerate therapy development for dry eye disease and other ocular surface disorders.

Zeiss has secured regulatory approvals to acquire DORC and will shift focus to integration implementation

Thompson will assume the presidency of the ASCRS, which is celebrating its 50th anniversary in 2024. The organization kicks off its 2024 annual meeting Friday at Boston Convention and Exhibition Center in Boston.

The company’s Lacrifill canalicular gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Researchers have linked ZIKV to ocular deformities in infants that include retinal lesions, microphthalmia, hemorrhagic retinopathy, retinal pigmented epithelium mottling, optic neuritis and hypoplasia of the optic nerve.

Zachary Robertson, MD, a retina specialist at the University of Texas Southwestern Medical Center talked with David Hutton of Ophthalmology Times about the upcoming solar eclipse and what potential damages the event could cause on the retina.

The 2 organizations to receive initial gifts will be Sight for Life and Eye Corps.

NEPTUNE represents the seventh positive Phase 2 study for brepocitinib with more than 1400 subjects and patients treated with brepocitinib in clinical trials. Brepocitinib was generally safe and well-tolerated in the study; no new safety and tolerability signals were identified.

Extended treatment intervals with bevacizumab preserved vision of many patients with high baseline vision.

The company announced it will share clinical data at Eyecelerator and the American Society of Cataract and Refractive Surgery 2024 Annual Meeting in Boston.

Three IOLs are evaluated in a randomised study

Multimodal imaging and a systemic work-up failed to identify any underlying disorder for the hemorrhages

The Osprey trial has started dosing while the Apteryx trial is anticipated to begin within the next few weeks.

According to the company, EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

Age-related macular degeneration continues to be a key development area for many pharmaceutical companies as the work to develop new treatment options and present data in the first few months of the year.

One year after implantation, the enduring IOP reduction remained consistent across all 3 dose strengths.